Patrick Lucy, Lykan Bioscience CEO

Two CD­MOs come to­geth­er as they look to ex­pand their reach in cell ther­a­py man­u­fac­tur­ing

As the cell ther­a­py field has ma­tured, the man­u­fac­tur­ing of such ther­a­pies be­comes a greater fo­cus for com­pa­nies small and large. Amid this growth, two CD­MOs have come to­geth­er in a merg­er to ex­pand their reach.

Lykan Bio­science, based in Mass­a­chu­setts, and RoslinCT, based in Ed­in­burgh, UK, will be­come a sin­gle ad­vanced ther­a­pies CD­MO. The new­ly com­bined group will of­fer process de­vel­op­ment ex­per­tise as well as cGMP man­u­fac­tur­ing for a broad range of au­tol­o­gous and al­lo­gene­ic cell ther­a­pies, along with gene edit­ing and in­duced pluripo­tent stem cell (iP­SC) ca­pa­bil­i­ties for cell ther­a­py de­vel­op­ment. Fi­nan­cial terms of the deal were not dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.